Knopp Neurosciences Presents Encouraging Trends in ALS Phase 2 Trial of KNS-760704

In a presentation at the annual meeting of the American Academy of Neurology, Knopp Neurosciences outlined more encouraging trends in the development of its Phase 2 study of KNS-760704 for ALS. The company reported that analysis showed a trend of reduced treatment failure over placebo. “Despite the limited sample size and treatment periods, ongoing review of the Phase 2 data shows consistently encouraging trends in both pre-specified and post hoc analysis,” said Dr. Merit Cudkowicz, Professor of Neurology at the Massachusetts General Hospital of Harvard Medical School, the study’s PI, in a BusinessWire release. “We are eager to initiate Phase 3 studies as soon as protocol development and other arrangements are completed.”


Share this: